RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the closing of its offering of $60 million aggregate principal amount of 5.5% convertible senior notes due 2028, which includes the exercise in full of the initial purchasers’ over-allotment option.
